Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors.
Tu HF, Kung YJ, Lim L, Tao J, Hu MH, Cheng M, Xing D, Wu TC, Hung CF |
Journal of biomedical science | 2024 |
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I, Kalafateli M, Triantos C |
International journal of molecular sciences | 2024 |
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Yi F, Cohen T, Zimmerman N, Dündar F, Zumbo P, Eltilib R, Brophy EJ, Arkin H, Feucht J, Gormally MV, Hackett CS, Kropp KN, Etxeberria I, Chandran SS, Park JH, Hsu KC, Sadelain M, Betel D, Klebanoff CA |
2024 | |
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML
Lo Presti V, Meringa A, Dunnebach E, van Velzen A, Moreira AV, Stam RW, Kotecha RS, Krippner-Heidenreich A, Heidenreich OT, Plantinga M, Cornel A, Sebestyen Z, Kuball J, van Til NP, Nierkens S |
Journal for ImmunoTherapy of Cancer | 2024 |
A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J, Zhang W, Tong J, Liu C, Zhang Q, Cao L, Yu J, Zhou A, Ma J |
Cancer Immunology, Immunotherapy | 2024 |
Functionalized nanowires for miRNA-mediated therapeutic programming of naïve T cells.
Yee Mon KJ, Kim S, Dai Z, West JD, Zhu H, Jain R, Grimson A, Rudd BD, Singh A |
Nature Nanotechnology | 2024 |
Metabolic dialogues: regulators of chimeric antigen receptor T cell function in the tumor microenvironment
Moraly J, Kondo T, Benzaoui M, DuSold J, Talluri S, Pouzolles MC, Chien C, Dardalhon V, Taylor N |
Molecular Oncology | 2024 |
Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y |
Naunyn-Schmiedeberg's archives of pharmacology | 2024 |
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy
Li T, Guo S, Xu C, Zhang M, Lyu C, Xu H, Hou Z, Zhang M, Li X, Ren J, Liu C, Kong D, Hao D, Wang G |
Journal for Immunotherapy of Cancer | 2024 |
Biomaterial-Based Therapeutic Delivery of Immune Cells
Dravid AA, Singh A, García AJ |
Advanced healthcare materials | 2024 |
Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy
Tsao ST, Gu M, Xiong Q, Deng Y, Deng T, Fu C, Zhao Z, Zhang H, Liu C, Zhong X, Xiang F, Huang F, Wang H |
Vaccines | 2024 |
Memory stem CD8+T cells in HIV/Mtb mono- and co-infection: characteristics, implications, and clinical significance
Xiao J, Wang F, Yan H, Wang B, Su B, Lu X, Zhang T |
Frontiers in Cellular and Infection Microbiology | 2024 |
Senescent T Cells in Age-Related Diseases
Yu PJ, Zhou M, Liu Y, Du J |
Aging and Disease | 2024 |